Prattes C, Leithner A, Szkandera J, Prattes G, Urban E, Eder-Halbedl A
Wien Klin Wochenschr. 2024; .
PMID: 39527259
DOI: 10.1007/s00508-024-02467-6.
Nagamine A, Araki T, Yashima H, Kamimura A, Shiraishi T, Yanagawa T
Oncol Lett. 2023; 25(2):70.
PMID: 36688106
PMC: 9843304.
DOI: 10.3892/ol.2022.13656.
Barreto J, Reid J, Thompson C, Mara K, Rule A, Kashani K
Clin Transl Sci. 2021; 15(1):105-117.
PMID: 34378331
PMC: 8742646.
DOI: 10.1111/cts.13125.
Panetta J, Roberts J, Huang J, Lin T, Daryani V, Harstead K
Br J Clin Pharmacol. 2019; 86(2):362-371.
PMID: 31657864
PMC: 7015755.
DOI: 10.1111/bcp.14160.
Barreto J, McClanahan A, Rule A, Thompson C, Frazee E
Case Rep Hematol. 2018; 2018:7169897.
PMID: 29780646
PMC: 5892267.
DOI: 10.1155/2018/7169897.
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
Mikkelsen T, Sparreboom A, Cheng C, Zhou Y, Boyett J, Raimondi S
J Clin Oncol. 2011; 29(13):1771-8.
PMID: 21444869
PMC: 3107765.
DOI: 10.1200/JCO.2010.32.5340.
Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.
Fleischhack G, Jaehde U, Bode U
Clin Pharmacokinet. 2005; 44(1):1-31.
PMID: 15634030
DOI: 10.2165/00003088-200544010-00001.
High-dose methotrexate: a clinical and pharmacokinetic evaluation. Treatment of advanced squamous cell carcinoma of the head and neck using a prospective mathematical model and pharmacokinetic surveillance.
Favre R, Monjanel S, Alfonsi M, Pradoura J, Clement S, Imbert A
Cancer Chemother Pharmacol. 1982; 9(3):156-60.
PMID: 7160050
DOI: 10.1007/BF00257744.
Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.
Howell S, Chu B, Wung W, Metha B, Mendelsohn J
J Clin Invest. 1981; 67(4):1161-70.
PMID: 6970753
PMC: 370677.
DOI: 10.1172/jci110130.
Synchronization of human leukemic cells: relevance for high-resolution chromosome banding.
Gallo J, Ordonez J, Brown G, Testa J
Hum Genet. 1984; 66(2-3):220-4.
PMID: 6585345
DOI: 10.1007/BF00286605.
Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.
Luyckx M, Cazin J, Brunet C, Gosselin P, Demaille M
Eur J Clin Pharmacol. 1985; 28(4):457-62.
PMID: 3839754
DOI: 10.1007/BF00544367.
Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate.
Umbach G, Spitzer G, Ajani J, Hug V, Thames H, Rudolph F
J Cancer Res Clin Oncol. 1986; 111(3):273-6.
PMID: 3733857
DOI: 10.1007/BF00389244.
Pharmacokinetics of anticancer drugs in children.
Crom W, Rodman J, Teresi M, Kavanagh R, Christensen M, Relling M
Clin Pharmacokinet. 1987; 12(3):168-213.
PMID: 3555940
DOI: 10.2165/00003088-198712030-00002.
Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.
Moore M, Erlichman C
Clin Pharmacokinet. 1987; 13(4):205-27.
PMID: 3311530
DOI: 10.2165/00003088-198713040-00001.
Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.
Borsi J, Schuler D, MOE P
Cancer Chemother Pharmacol. 1988; 22(1):33-5.
PMID: 3260832
DOI: 10.1007/BF00254177.
An indication of possible impending toxicity during moderately high dose methotrexate infusions.
Paxton J, Stephens E, WOOD H
Br J Clin Pharmacol. 1978; 6(6):551-2.
PMID: 569491
PMC: 1429700.
DOI: 10.1111/j.1365-2125.1978.tb00887.x.
Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.
Cohen H, Jaffe N
Cancer Chemother Pharmacol. 1978; 1(1):61-4.
PMID: 373909
DOI: 10.1007/BF00253148.
Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.
Goh T, Wong K, Lampkin B, OLeary J, Gnarra D
Cancer Chemother Pharmacol. 1979; 3(3):177-80.
PMID: 316745
DOI: 10.1007/BF00262419.
Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.
Evans W, Pratt C, Taylor R, Barker L, Crom W
Cancer Chemother Pharmacol. 1979; 3(3):161-6.
PMID: 316744
DOI: 10.1007/BF00262416.
Antineoplastic drugs: clinical pharmacology and therapeutic use.
Bender R, Zwelling L, Doroshow J, Locker G, Hande K, Murinson D
Drugs. 1978; 16(1):46-87.
PMID: 78795
DOI: 10.2165/00003495-197816010-00003.
